AngioDynamics (NASDAQ:ANGO) Sets New 1-Year High – What’s Next?

AngioDynamics, Inc. (NASDAQ:ANGO) reached a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $16.29 and last traded at $16.00, with a volume of 7297 shares. The stock had previously closed at $16.13.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the stock. Wall Street Zen raised shares of AngioDynamics from a “hold” rating to a “buy” rating in a research report on Saturday, August 22nd. HC Wainwright upped their price objective on shares of AngioDynamics from $16.00 to $19.00 and gave the stock a “buy” rating in a research report on Wednesday, July 15th. Zacks Research lowered shares of AngioDynamics from a “hold” rating to a “strong sell” rating in a research note on Thursday, July 16th. Canaccord Genuity Group lifted their target price on shares of AngioDynamics from $16.00 to $20.00 and gave the stock a “buy” rating in a research report on Wednesday, July 15th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of AngioDynamics in a research note on Friday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and two have given a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $19.50.

AngioDynamics Price Performance

The firm’s 50 day moving average price is $14.41 and its two-hundred day moving average price is $12.29. The stock has a market cap of $657.11 million, a PE ratio of -18.22 and a beta of 0.33.

AngioDynamics (NASDAQ:ANGO) last announced its quarterly earnings results on Tuesday, July 14th. The medical instruments supplier reported ($0.07) EPS for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.04. AngioDynamics had a negative net margin of 11.48% and a negative return on equity of 5.73%. The company had revenue of $86.61 million for the quarter, compared to analysts’ expectations of $80.24 million. AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS. Analysts anticipate that AngioDynamics, Inc. will post -0.25 earnings per share for the current year.

Insider Buying and Selling at AngioDynamics

In related news, SVP Warren Nighan, Jr. sold 23,370 shares of the business’s stock in a transaction on Thursday, July 30th. The stock was sold at an average price of $14.72, for a total transaction of $344,006.40. Following the sale, the senior vice president directly owned 64,745 shares in the company, valued at approximately $953,046.40. The trade was a 26.52% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 6.00% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in ANGO. Farther Finance Advisors LLC increased its position in shares of AngioDynamics by 146.4% during the fourth quarter. Farther Finance Advisors LLC now owns 2,018 shares of the medical instruments supplier’s stock valued at $26,000 after buying an additional 1,199 shares during the period. Kemnay Advisory Services Inc. purchased a new stake in shares of AngioDynamics in the fourth quarter worth about $27,000. State of Wyoming bought a new position in shares of AngioDynamics in the second quarter valued at approximately $31,000. Legal & General Group Plc bought a new position in shares of AngioDynamics in the second quarter valued at approximately $45,000. Finally, Russell Investments Group Ltd. grew its stake in AngioDynamics by 329.5% during the third quarter. Russell Investments Group Ltd. now owns 4,188 shares of the medical instruments supplier’s stock valued at $47,000 after acquiring an additional 3,213 shares in the last quarter. Institutional investors own 89.43% of the company’s stock.

AngioDynamics Company Profile

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.